# A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II

Study · id `cardio:ct-nct02890160` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02890160](<https://clinicaltrials.gov/study/NCT02890160>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02890160

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 430 participants.

## Technical summary

Registry record NCT02890160. Randomized; single masking; primary purpose treatment. Start 2017-08-24 (actual); primary completion 2020-10-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 430 participants (enrolled count; ClinicalTrials.gov record NCT02890160, source copy `cardio:ctgov-nct02890160-2026-05-29`, retrieved 2026-10-26)
- Started: 2017-08-24 (actual) (ClinicalTrials.gov record NCT02890160, source copy `cardio:ctgov-nct02890160-2026-05-29`, retrieved 2026-10-26)
- Primary completion: 2020-10-31 (actual) (ClinicalTrials.gov record NCT02890160, source copy `cardio:ctgov-nct02890160-2026-05-29`, retrieved 2026-10-26)
- Completion: 2024-10-03 (actual) (ClinicalTrials.gov record NCT02890160, source copy `cardio:ctgov-nct02890160-2026-05-29`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02890160, source copy `cardio:ctgov-nct02890160-2026-05-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02890160-2026-05-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II
- Acronym: FUTURE-II
- Condition: Coronary Artery Disease
- Intervention (Device): Firesorb
- Intervention (Device): XIENCE
- Lead sponsor: Shanghai MicroPort Medical (Group) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Shanghai MicroPort Medical (Group) Co., Ltd. (`cardio:org-shanghai-microport-medical-group-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With Coronary Artery Disease: FUTURE-II Trial (`cardio:pubmed-34238555`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: bf7179f0c8a6403ed7d5de936576427e81ec588707f2b5ff806d967ea6abf640
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
